Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Excess skin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Excess skin. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-000514-21 Sponsor Protocol Number: AG-PH3 Start Date*: 2007-01-02
    Sponsor Name:CIS bio International
    Full Title: Multicenter, randomized, open-label, clinical study on the agreement of Scintimun® Granulocyte and labeled 99mTc-White Blood Cells in diagnosing infection/inflammation by immunoscintigraphy in peri...
    Medical condition: Patients with suspected or documented osteomyelitis in the peripheral skeleton including patients with loosening of joint prosthesis or diabetic foot. At least one of following signs or symptoms is...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-000877-10 Sponsor Protocol Number: MWTBTXA Start Date*: 2021-07-14
    Sponsor Name:Bispebjerg Hospital, Department of Dermatology
    Full Title: Longevity of microwave thermolysis and botulinum toxin A for treatment of axillary hyperhidrosis: a randomized intra-individual trial
    Medical condition: Axillary hyperhidrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10020642 Hyperhidrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-000769-49 Sponsor Protocol Number: AGO/2008/001 Start Date*: 2008-06-25
    Sponsor Name:University Hospital Ghent
    Full Title: Unicentrische vergelijkende studie van suctie curretage met standaard BOTOX injectie bij de behandeling van patiënten met essentiële axillaire hyperhidrosis: vergelijking van efficaciteit, duur van...
    Medical condition: behandeling van axillaire hyperhydrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020642 Hyperhidrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003132-30 Sponsor Protocol Number: BTXHH11 Start Date*: 2011-09-09
    Sponsor Name:Svettmottagningen Hidroskliniken, Stockholm
    Full Title: Botulinum toxin treatment in craniofacial, inguinal, palmar, plantar and truncal hyperhidrosis, a randomized, double blind, placebo controlled study.
    Medical condition: Hyperhidrosis-craniofacial, inguinal, palmar, plantar and truncal.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10020642 Hyperhidrosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002052-27 Sponsor Protocol Number: DRM04-HH04 Start Date*: 2015-10-14
    Sponsor Name:Dermira, Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED EFFICACY AND SAFETY STUDY OF DRM04 IN SUBJECTS WITH AXILLARY HYPERHIDROSIS
    Medical condition: Primary axillary hyperhidrosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10020642 Hyperhidrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002163-42 Sponsor Protocol Number: DRM04-HH06 Start Date*: 2015-10-13
    Sponsor Name:Dermira, Inc.
    Full Title: AN OPEN-LABEL STUDY ASSESSING LONG-TERM SAFETY OF DRM04 IN SUBJECTS WITH PRIMARY AXILLARY HYPERHIDROSIS
    Medical condition: Primary axillary hyperhidrosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10020642 Hyperhidrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004293-10 Sponsor Protocol Number: REH-TOX-2013-01 Start Date*: 2014-06-03
    Sponsor Name:Hospital Universitari de Tarragona Joan XXIII
    Full Title: Efficacy of treatment by iontophoresis of botulinum toxin type A free from complexing proteins for stump hyperhidrosis
    Medical condition: Stump hyperhidrosis in lower limb amputees
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10020642 Hyperhidrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000922-46 Sponsor Protocol Number: GPBK-08/2018 Start Date*: 2023-01-27
    Sponsor Name:Dr. August Wolff GmbH & Co. KG Arzneimittel
    Full Title: An Open-Label, Uncontrolled, Multicenter Study to Evaluate the Safety, Local Tolerability, Systemic Exposure, and Efficacy of 1% GPB Cream in Adolescents With Severe Primary Axillary Hyperhidrosis ...
    Medical condition: Severe primary axillary hyperhidrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10020642 Hyperhidrosis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013684-19 Sponsor Protocol Number: Concentration-BTX Start Date*: 2009-08-12
    Sponsor Name:Uppsala läns landsting
    Full Title: Studie av botulinumtoxiners anhidrotiska (svettreducerande) effekt beroende på använd koncentration.
    Medical condition: Studien kommer att utföras på friska försökspersoner. Anhidrotisk (svettreducerande) effekt samt durationen av denna kommer att undersökas efter injektioner med botulinumtoxin. Resultaten från stu...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020642 Hyperhidrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023799-21 Sponsor Protocol Number: H9X-MC-GBDJ Start Date*: 2011-10-06
    Sponsor Name:Eli Lilly & Company
    Full Title: The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)
    Medical condition: Cardiovascular events in patients with Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004860 10012654 Diabetic complications cardiovascular HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed) GB (Completed) PL (Completed) ES (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001447-39 Sponsor Protocol Number: AB15003 Start Date*: 2019-10-21
    Sponsor Name:AB SCIENCE
    Full Title: A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase III study to compare efficacy and safety ...
    Medical condition: Smouldering or Indolent Severe Systemic mastocytosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Prematurely Ended) PL (Trial now transitioned) RO (Ongoing) LT (Completed) NL (Temporarily Halted) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003087-20 Sponsor Protocol Number: 800_OPBG_2014 Start Date*: 2014-11-12
    Sponsor Name:IRCCS Ospedale Pediatrico Bambino Gesù
    Full Title: Determination of Plasmatic and CSF Levels Of High Doses Of Micafungin in Neonates Suffering from Systemic Candidiasis and/or Candida meningitis.
    Medical condition: Systemic Candidiasis and/or Candida Meningitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10027238 Meningitis fungal NOS LLT
    17.0 100000004852 10027237 Meningeal fungal infections HLT
    17.0 100000004862 10042941 Systemic fungal infection NOS LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004718-32 Sponsor Protocol Number: NL72607.041.20 Start Date*: 2020-10-09
    Sponsor Name:UMC Utrecht
    Full Title: Upfront autologous hematopoietic stem cell transplantation versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis: an international multicentre, open-label, randomized co...
    Medical condition: Diffuse cutaneous systemic sclerosis according to the ACR/EULAR criteria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004534-28 Sponsor Protocol Number: Hyp1-18/2016 Start Date*: 2018-08-09
    Sponsor Name:Dr. August Wolff GmbH & Co. KG Arzneimittel
    Full Title: Combined Randomized, Double-Blind, Dose-Confirming Phase 3a Study in Parallel Design to Assess the Efficacy and Safety of Topical 4-Week Treatment With 1% GPB Cream vs Placebo and Open-Label Phase...
    Medical condition: Severe primary axillary hyperhidrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10020642 Hyperhidrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) HU (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002454-36 Sponsor Protocol Number: 2125-MEL-301 Start Date*: 2018-04-28
    Sponsor Name:Idera Pharmaceuticals, Inc.
    Full Title: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma
    Medical condition: Refractory melanoma is a malignant tumor of melanocytes which originates predominantly from skin.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004113-85 Sponsor Protocol Number: PA101-SM-02 Start Date*: 2015-04-16
    Sponsor Name:Patara Pharma, LLC
    Full Title: Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study with PA101 in Patients with Indolent Systemic Mastocytosis
    Medical condition: Indolent Systemic Mastocytosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10042949 Systemic mastocytosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005023-11 Sponsor Protocol Number: EMR200017-014 Start Date*: 2016-07-08
    Sponsor Name:Merck KGaA
    Full Title: A Phase II, randomized, double-blind, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated intersti...
    Medical condition: Systemic sclerosis-associated interstitial lung disease (SSc-ILD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10025109 Lung involvement in systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002836-97 Sponsor Protocol Number: 240193 Start Date*: 2012-12-20
    Sponsor Name:Tartu University Hospital
    Full Title: Pharmacokinetics of penicillin, ampicillin and gentamicin in near- term and full-term neonates
    Medical condition: neonatal sepsis, pneumonia and meningitis
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007813-35 Sponsor Protocol Number: TBA Start Date*: 2008-06-16
    Sponsor Name:University Hospital of North Tees and Hartlepool
    Full Title: Randomised Controlled Trial of the Use of Topical Application of Tranexamic Acid in Primary Cemented Total Knee Replacement (TRANX-K).
    Medical condition: In this study Tranexamic acid efficacy in reducing blood loss will be investigated in total knee replacement.Tranexamic acid will be applied topically to the exposed tissue around the knee joint pr...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023227 Joint replacement LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005206-10 Sponsor Protocol Number: PR200-104 Start Date*: 2022-03-14
    Sponsor Name:Prometheus Biosciences, Inc.
    Full Title: A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD)
    Medical condition: Systemic sclerosis associated with interstitial lung disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004855 10025109 Lung involvement in systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) NO (Completed) NL (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 04:14:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA